Translator Disclaimer
12 January 1995 Pharmacokinetics of the far red absorbing octa-alpha-butyloxy-zinc phthalocyanine in Lewis lung carcinoma bearing mice
Author Affiliations +
Proceedings Volume 2325, Photodynamic Therapy of Cancer II; (1995)
Event: International Symposium on Biomedical Optics Europe '94, 1994, Lille, France
The newly synthesized potential photosensitizer octa-(alpha) -butyloxy-zinc phthalocyanine (8-(alpha) -bo-ZnPc) is characterized by a high absorption coefficient at the far red wavelength 735 nm and a good singlet oxygen quantum yield. The pharmacokinetics of 8- (alpha) -bo-ZnPc were studied on the Lewis lung carcinoma in mice after i.v. administration of 7.8 micrometers ole/kg body weight solubilized in PBS with 1% Tween 80 at 2, 6, 12, 24, 48 and 168 hour incubation intervals. The accumulated dye contents were chemically extracted from selected tissues and the concentrations were measured by absorption spectroscopy. The parenchymatous organs, liver and spleen, showed maximum 8-(alpha) -bo-ZnPc concentrations after 6 h incubation (33 nmole/g liver and 5 nmole/g spleen, respectively). An extensive uptake was detected in the lung where concentrations higher than 90 nmole/g tissue were measured in the 6, 12, 24, and 48 hour extracts. The malignant tissue did not accumulate higher 8-(alpha) -bo-ZnPc concentrations than 0.4 nmole/g tumor during the entire investigation period. The dye contents extracted from muscle, representing normal tumor surrounding tissue, and skin were even lower and never exceeded 0.11 nmole/g muscle (6 h) and 0.21 nmole/g skin (2 h), respectively.
© (1995) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Cathrin Dressler, M. Samy Ismail, Christian Nowak, Ralf Herter, Rainier G. Senz, Roland Hagemann, Beate Roeder, and Hans-Peter Berlien "Pharmacokinetics of the far red absorbing octa-alpha-butyloxy-zinc phthalocyanine in Lewis lung carcinoma bearing mice", Proc. SPIE 2325, Photodynamic Therapy of Cancer II, (12 January 1995);

Back to Top